Volitionrx SEC Filings

VolitionRx Limited is increasing its at-the-market stock offering to permit sales of up to $30,000,000 of common stock under an amended Capital on Demand Sales Agreement with JonesTrading. The company initially registered up to $7,500,000 of common stock and has sold 837,824 shares for gross proceeds of $527,141.26 through JonesTrading under the original agreement. This supplement updates the existing shelf registration so the company can continue issuing shares from time to time on the NYSE American, where its stock trades under the symbol VNRX. VolitionRx also notes that, as of June 20, 2025, its public float was $88,258,714, based on 103,982,020 shares outstanding and 95,933,385 non-affiliate shares at a price of $0.92 per share, meaning it is no longer subject to the Form S-3 I.B.6 size limits.

Lagoda Investment Management, L.P. reports that its managed accounts held 11,705,000 shares of VolitionRX Ltd common stock as of June 30, 2025, representing 11.3% of the outstanding shares. The filing states the Reporting Person has sole voting and sole dispositive power over all 11,705,000 shares. The report cites 103,982,020 shares outstanding for VolitionRX used to calculate the percentage. The Schedule 13G/A indicates the stake is held in the ordinary course of business and was not acquired to influence control of the issuer.

On 08/05/2025, VolitionRx Ltd. (VNRX) director Guy Archibald Innes filed Form 4 reporting the purchase of 78,125 common shares at $0.64 per share, executed through the company’s registered direct offering. The transaction lifts his direct holding to 966,814 shares.

The filing also lists significant indirect ownership: 1,400,000 shares held by The Innes Family Bare Trust 2023 (where Innes is trustee), 356,000 shares held by The Dill Faulkes Educational Trust Ltd., and a combined 618,014 shares registered in the names of his son (309,006) and daughter (309,008). Innes shares voting/dispositive control over these blocks and disclaims beneficial ownership of the DFET position beyond any pecuniary interest.

No derivative securities were reported, and the form was signed on 08/06/2025.

VolitionRx Ltd. (VNRX) – Form 4 filing

On 08/05/2025, President, CEO & Director Cameron John Reynolds purchased 78,125 shares of common stock at $0.64 per share during the company’s registered direct offering (transaction code “P”). The acquisition raises his direct holdings to 2,609,847 shares. Reynolds also controls 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse, bringing his total beneficial ownership to roughly 3.65 million shares. No derivative securities were exercised or sold, and no dispositions were reported.

This insider buy represents an out-of-pocket investment of approximately $50,000, strengthening management’s alignment with shareholders. The shares were obtained via a primary issuance, indicating additional capital raised by the company.

Form 4 discloses that Salvatore T. Butera, CEO of Volition Veterinary and an officer of VolitionRx (VNRX), had 6,393 common shares automatically withheld on 01-Aug-2025 (code “F”) to cover taxes due on the vesting of 23,377 restricted stock units received in lieu of cash compensation. The withheld shares were cancelled by the company; neither the insider nor VolitionRx executed an open-market sale. After the transaction Mr. Butera owns 303,524 shares directly and 99,350 shares jointly with his spouse, keeping his overall economic stake largely intact. No derivative securities were transacted. Because the action was tax-related and not a discretionary sale or purchase, it carries limited insight into management’s view of valuation, but it does confirm the continued equity alignment of a key executive.

On 08/01/2025, VolitionRX Ltd. (VNRX) Chief Medical Officer Andrew Retter filed a Form 4 detailing an administrative, tax-related share withholding.

• 6,142 common shares were automatically withheld and cancelled (Transaction Code F) at an indicated price of $0.64 to satisfy tax obligations arising from the vesting of 13,069 restricted stock units that had been granted in lieu of cash compensation.
• Following the transaction, Retter’s direct beneficial ownership totals 131,632 common shares.

No open-market purchase or sale occurred, and the tiny reduction in outstanding shares is immaterial to VNRX’s capitalization. The filing therefore carries neutral informational value regarding insider sentiment or company fundamentals.

Transaction summary: Ann-Louise Batchelor, Group Chief Marketing Officer, filed a Form 4 for VolitionRx Ltd (VNRX) reporting activity dated 08/01/2025.

Details: The filing states 18,341 restricted stock units were settled in lieu of cash compensation and that 8,620 shares were retained by VolitionRx for cancellation to satisfy the reporting person’s tax withholding obligations. The filing explicitly states no shares were sold. Following the reported transaction, Batchelor beneficially owns 132,486 shares directly and 29,406 shares indirectly (by spouse). The table shows a price of $0.64. Form signed 08/05/2025.

VolitionRx Ltd. (VNRX) – Form 4 filing

Chief Commercial Officer Gael Forterre reported a single Code F transaction on 1 Aug 2025, reflecting shares surrendered to the company to cover taxes upon settlement of 6,690 restricted stock units received in lieu of cash compensation. 2,766 common shares were withheld at an implied price of $0.64 and therefore cancelled; no open-market sale occurred.

Following the withholding, Forterre’s holdings stand at 156,700 directly-owned shares. He also reports 5,000 shares held indirectly by his spouse and 32,500 shares managed through Armorica Partners, LLC, over which he exercises voting and dispositive control. The filing represents routine administrative tax withholding and does not signal a change in insider ownership intent or corporate outlook.